qfx

The Securities and Exchange Commission filing, dated February 17, 2026, confirms the aforementioned share acquisition. The value, $10.80 million, is a fixed point in a shifting landscape. One can almost feel the weight of that sum, not as capital, but as an arbitrary designation within a larger, unyielding mechanism.

Of course, even in retirement, the man couldn’t help but tinker. It’s the sort of compulsion I recognize in myself – the need to rearrange the spice rack, to re-alphabetize the bookshelf, even when nobody else notices. And, predictably, that tinkering involved a significant shuffling of Berkshire Hathaway’s holdings. It wasn’t a complete teardown, mind you. Just a strategic pruning and a rather interesting new planting. I always thought the man was a bit of a gardener at heart. A very, very wealthy gardener.

But here’s the rub. The stock, despite its recent acrobatics, hasn’t exactly become a pauper’s delight. At one point, it traded at a price that would make a Fabergé egg blush. Valuation has retreated somewhat, naturally, as gravity exerts its inevitable influence. Still, ‘cheap’ remains a word one hesitates to apply. And yet… perhaps a bargain lurks within this digital labyrinth.

The SEC filing, that modern equivalent of a palimpsest, confirms the transaction. Covalis, a name which evokes the image of a cartographer tracing the boundaries of fortune, has thus marked its claim upon a portion of Core Scientific’s domain. The increase in position value—a fleeting measure of ephemeral worth—is noted, but feels, somehow, insufficient to the task of comprehension.